

AMENDMENTS**In the Claims:**

This listing of claims replaces all prior versions, and listings, of claims in the application.

1. (canceled).
2. (original) A therapeutic agent for myeloma, said agent comprising, as an active ingredient:
 - (1) interferon- α or interferon- γ , and
 - (2) an antibody that specifically binds to a protein having the amino acid sequence as set forth in SEQ ID NO: 2, and that has a cytotoxic activity.
3. (original) The therapeutic agent according to claim 2 wherein said myeloma is multiple myeloma.
4. (original) The therapeutic agent according to claim 2 or 3 wherein said antibody is a monoclonal antibody.
5. (original) The therapeutic agent according to claim 4 wherein said antibody has a cytotoxic activity.
6. (original) The therapeutic agent according to claim 2 wherein said antibody is a chimeric antibody or a humanized antibody.
7. (original) The therapeutic agent according to claim 5 wherein said antibody is anti-HM1.24 antibody.
8. (original) The therapeutic agent according to claim 6 wherein said chimeric antibody or humanized antibody is chimeric anti-HM1.24 antibody or humanized anti-HM1.24 antibody.

9. (withdrawn) An enhancer for expression in myeloma cell of a protein (HM1.24 antigen) having the amino acid sequence as set forth in SEQ ID NO: 2, said enhancer comprising IRF-2 protein as an active ingredient.

10. (withdrawn) An activating agent for the HM1.24 promoter, said agent comprising IRF-2 protein as an active ingredient.

11. (withdrawn) A therapeutic agent for myeloma comprising, as active ingredient:

(1) IRF-2 protein, and

(2) an antibody that specifically binds to a protein having the amino acid sequence as set forth in SEQ ID NO: 2, and that has a cytotoxic activity.

12. (withdrawn) The therapeutic agent according to claim 11 wherein said myeloma is multiple myeloma.

13. (withdrawn) The therapeutic agent according to claim 11 or 12 wherein said antibody is a monoclonal antibody.

14. (withdrawn) The therapeutic agent according to claim 13 wherein said antibody has cytotoxic activity.

15. (withdrawn) The therapeutic agent according to claim 11 wherein said antibody is a chimeric antibody or a humanized antibody.

16. (withdrawn) The therapeutic agent according to claim 14 wherein said antibody is anti-HM1.24 antibody.

17. (withdrawn) The therapeutic agent according to claim 15 wherein said chimeric antibody or humanized antibody is chimeric anti-HM1.24 antibody or humanized anti-HM1.24 antibody.

18. (withdrawn) An enhancer for expression in myeloma cell of HM1.24 antigen, said enhancer comprising, as an active ingredient, a compound that enhances the expression of IRF-2 protein.

19. (withdrawn) An activating agent for the HM1.24 promoter said agent comprising, as an active ingredient, a compound that enhances the expression of IRF-2 protein.

20. (withdrawn) A method of screening expression enhancers of HM1.24 antigen.

21. (withdrawn) A kit comprising:

(1) an antibody that specifically binds to a protein having the amino acid sequence as set forth in SEQ ID NO: 2, and that has a cytotoxic activity; and

(2) an instruction manual that directs the administration to the patient of the above antibody in combination with a pharmaceutical agent that enhances the expression of a protein having the amino acid sequence as set forth in SEQ ID NO: 2.

22. (withdrawn) The kit according to claim 21 wherein said myeloma is multiple myeloma.

23. (withdrawn) The kit according to claim 21 wherein said antibody is humanized anti-HM1.24 antibody.

24. (withdrawn) The kit according to claim 21 wherein said pharmaceutical agent that enhances the expression of a protein having the amino acid sequence as set forth in SEQ ID NO: 2 is interferon- α or interferon- γ .

25. (withdrawn) A pharmaceutical composition for the treatment of a patient with myeloma comprising an antibody that specifically binds to a protein having the amino acid sequence as set forth in SEQ ID NO: 2 and that has a cytotoxic activity, wherein said composition is administered to the patient in combination with a pharmaceutical agent that enhances the expression of a protein having the amino acid sequence as set forth in SEQ ID NO: 2.

26. (withdrawn) The pharmaceutical composition according to claim 25 wherein said myeloma is multiple myeloma.

27. (withdrawn) The pharmaceutical composition according to claim 25 wherein said antibody is humanized anti-HM1.24 antibody.

28. (withdrawn) The pharmaceutical composition according to claim 25 wherein said pharmaceutical agent that enhances the expression of a protein having the amino acid sequence as set forth in SEQ ID NO: 2 is interferon- α or interferon- γ .